Acumen Pharmaceuticals, Inc. (ABOS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Acumen Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Acumen Pharmaceuticals, Inc. (ABOS) has returned 11.85% so far this year and 114.55% over the past 12 months.

Based on dividend-adjusted daily data since Jul 1, 2021, ABOS's average daily return is -0.01%, while the average monthly return is -0.49%.

Historically, 39% of months were positive and 61% were negative. The best month was Sep 2022 with a return of +76.3%, while the worst month was Oct 2023 at -54.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, ABOS closed higher 45% of trading days. The best single day was Sep 28, 2022 with a return of +103.8%, while the worst single day was Oct 27, 2023 at -24.8%.

Acumen Pharmaceuticals, Inc. has an annualized alpha of -15.96%, beta of 1.44, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since July 02, 2021.

• This stock participated in 190.23% of S&P 500 Index downside but only 9.62% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ABOS ranks 80 for risk / return — in the top 80% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Acumen Pharmaceuticals, Inc. (ABOS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Acumen Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Acumen Pharmaceuticals, Inc. was 95.56%, occurring on Apr 17, 2025. The portfolio has not yet recovered.

The current Acumen Pharmaceuticals, Inc. drawdown is 88.36%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Acumen Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Acumen Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.